Natera seeks Japan PMDA approval for Signatera test in muscle-invasive bladder cancer

• Natera filed Signatera with Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
• The submission follows PMDA approval for Signatera in colorectal cancer in June.
• Natera cited IMvigor011 Phase 3 trial data supporting the muscle-invasive bladder cancer filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608050600BIZWIRE_USPR_____20260805_BW954256) on August 05, 2026, and is solely responsible for the information contained therein.